The capacity of metformin to activate AMPK (AMP-activated protein kinase) has been suggested to constitute an insulin-independent mechanism of inhibitory effect of metformin on proliferation of cancer cells, directly connected with promotion of the inhibition of the AMPK down-stream mammalian effector target of rapamycin (mTOR) [48-53]. The gene discussed is MTOR; the disease is cancer.